Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2005

View Archived Issues

MN-001 shows a good safety profile in healthy volunteers

Dosing begins in phase I study of CCR5 mAb in HIV patients

StemCells works to lift clinical hold on proposed phase I study of HuCNS-SC

PRX-03140 enters phase Ib studies for Alzheimer's

Theratechnologies plans phase III trials for ThGRF

Rigel completes phase I study of R-406

Adenosine A2A receptor agonist/PDE IV inhibitor combination therapy enhances cardioprotection

Antidepressants inhibit steroid transporters and evoke negative feedback on the HPA axis

Sucampo submits lubiprostone NDA

PTC-124 receives fast track status for cystic fibrosis

Sanofi pasteur's new polio vaccine licensed for use

Yamanouchi and Fujisawa form Astellas Pharma

Antiangiogenic actions of oral lenalidomide in rats

New analgesic agents developed at GSK and Euroceltique

Valentis initiates phase IIb study of VLTS-934 for peripheral arterial disease

Memory nominates new drug candidate MEM-63908

Genentech claims new treatments for immunological disorders

Landmark study evaluates Provacel stem cell product in cardiac patients

Antibacterial CY-403 enters preclinical testing

Chinese launch of Bilive vaccine

4SC concludes phase I studies for SC-12267

GSK discloses novel antiinflammatory glucocorticosteroids

Outline of products under development by MediciNova

FDA approves Asmanex for once daily management of asthma

New data on the anxiolytic effects of pregabalin in patients with GAD

New intravenous formulation of Nexium receives FDA approval

Novo Nordisk receives extended E.U. approvals for diabetes drugs

Studies assess gabapentin in cutaneous, postoperative and neuropathic pain

Lamotrigine efficacy, tolerability examined in painful diabetic neuropathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...